H. Lee Moffitt Cancer Center & Research Institute

A New Frontier in Cancer Treatment: Azra AI Partners with CancerX to Harness the Power of AI

Retrieved on: 
Tuesday, November 7, 2023

CancerX was announced by U.S. President Joe Biden and Dr. Jill Biden in February 2023 as part of the White House's reignited national Cancer Moonshot .

Key Points: 
  • CancerX was announced by U.S. President Joe Biden and Dr. Jill Biden in February 2023 as part of the White House's reignited national Cancer Moonshot .
  • CancerX is a collaboration of leaders in the oncology and digital health space to set priorities and practices that will help harness the full power of innovation to achieve the goals of the Cancer Moonshot.
  • "Multi-stakeholder collaboration is critical to harness the potential of digital innovation in the fight against cancer, and we're honored to partner with Azra AI to achieve the ambitious goals of CancerX," said Smit Patel, associate program director, DiMe.
  • "At Azra AI, we’re profoundly inspired to join forces with CancerX, united in our commitment to accelerate groundbreaking cancer innovation.

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023

Retrieved on: 
Friday, November 3, 2023

New clinical data will also be reported from the company’s ongoing Phase 1 trial evaluating its second candidate, CUE-102, for the treatment of Wilms’ Tumor 1 positive (WT1+) recurrent/metastatic cancers.

Key Points: 
  • New clinical data will also be reported from the company’s ongoing Phase 1 trial evaluating its second candidate, CUE-102, for the treatment of Wilms’ Tumor 1 positive (WT1+) recurrent/metastatic cancers.
  • I look forward to evaluating the trial results as they continue to mature and remain highly encouraged by the observations to date.
  • Two patients at the 2mg/kg dose, one with gastric cancer and one with ovarian cancer have demonstrated reduction in tumor burden.
  • Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.

Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of Hematology

Retrieved on: 
Thursday, November 2, 2023

“All CAR T cells require lymphodepletion to support the expansion and persistence needed to eradicate malignant cells.

Key Points: 
  • “All CAR T cells require lymphodepletion to support the expansion and persistence needed to eradicate malignant cells.
  • Data from the 12 patients, a subset of these 33 CAR T naïve patients, who received the regimen being utilized in ongoing Phase 2 trials was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
  • This study compared expansion kinetics among 11 allogeneic CAR T recipients treated with investigational ALLO-501A in the ALPHA2 trial.
  • Results of this study could help define strategies to improve allogeneic CAR T expansion, persistence, and efficacy.

Geron IMerge Phase 3 Presentations at Upcoming ASH Annual Meeting Reinforce Significant Durability and Breadth of Effect of Imetelstat in Lower Risk MDS

Retrieved on: 
Thursday, November 2, 2023

Four abstracts have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting taking place from December 9-12 in San Diego, California and virtually.

Key Points: 
  • Four abstracts have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting taking place from December 9-12 in San Diego, California and virtually.
  • “Additionally, our abstract showcasing a real-world data population level analysis of over 5,000 lower risk MDS patients adds to the significant literature suggesting a correlation between TI and improvement in survival.
  • This analysis suggests imetelstat has clinical activity in lower risk MDS patients independent of risk categories.
  • Achievement of durable TI was associated with improved survival, supporting the clinical benefit of achieving transfusion independence in lower risk MDS.

GC Cell Joins U.S Cancer Moonshot Project

Retrieved on: 
Wednesday, October 25, 2023

YONGIN, South Korea, Oct. 24, 2023 /PRNewswire/ -- GC Cell, led by CEO James Park, has announced its participation in CancerX, part of the U.S. Cancer Moonshot project. The Cancer Moonshot, an initiative by the Biden administration, aims to reduce cancer patient mortality rates by over 50% over the next 25 years. In February of this year, CancerX, a public-private collaboration led by the Moffitt Cancer Center and the Digital Medicine Society, was established to boost innovation in the fight against cancer as part of the reignited Cancer Moonshot.

Key Points: 
  • YONGIN, South Korea, Oct. 24, 2023 /PRNewswire/ -- GC Cell, led by CEO James Park, has announced its participation in CancerX, part of the U.S. Cancer Moonshot project.
  • The Cancer Moonshot, an initiative by the Biden administration, aims to reduce cancer patient mortality rates by over 50% over the next 25 years.
  • In February of this year, CancerX, a public-private collaboration led by the Moffitt Cancer Center and the Digital Medicine Society, was established to boost innovation in the fight against cancer as part of the reignited Cancer Moonshot.
  • Through Cancer Moonshot participation, GC Cell aims to highlight the importance and potential of cell therapy in cancer treatment.

Immuno-Oncology360º Announces 2024 Keynotes and Featured Speakers for the 10th Annual NYC Meeting

Retrieved on: 
Thursday, October 19, 2023

NEW YORK, Oct. 19, 2023 /PRNewswire-PRWeb/ -- The Conference Forum today announced the launch of the 10th annual Immuno-Oncology 360º Summit (IO360°) taking place February 27-29, 2024, at New York Marriott Brooklyn Bridge, in Brooklyn, NY.

Key Points: 
  • The Conference Forum announced the IO360º Summit's 2024 keynotes and featured speakers for its 10th annual conference.
  • NEW YORK, Oct. 19, 2023 /PRNewswire-PRWeb/ -- The Conference Forum today announced the launch of the 10th annual Immuno-Oncology 360º Summit (IO360°) taking place February 27-29, 2024, at New York Marriott Brooklyn Bridge, in Brooklyn, NY.
  • The IO360° 2024 keynotes include:
    Genentech's Ira Mellman, PhD, VP, Cancer Immunology, will speak on the roles of data mining and AI, and other clinical and translational data, in discovery and trial design.
  • "The IO360º conference presents the latest data impacting the IO landscape and for the 10th annual event, we are pleased to announce the extraordinary leadership advancing this space.

Trinity Investors Continue Investment in Trammell Crow Residential’s Attainable Housing Strategy with New Development in North Tampa

Retrieved on: 
Wednesday, October 11, 2023

SOUTHLAKE, Texas, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Trinity Investors of Southlake, Texas, has partnered with Trammell Crow Residential to expand their Class A attainable housing strategy in Tampa, Florida.

Key Points: 
  • SOUTHLAKE, Texas, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Trinity Investors of Southlake, Texas, has partnered with Trammell Crow Residential to expand their Class A attainable housing strategy in Tampa, Florida.
  • This investment comes on the heels of Trinity Investors and Trammell Crow Residential’s 2020 partnership to develop Allora Friendswood, a similar 249-unit garden-style apartment community that was successfully constructed and sold in 17 months.
  • “Our first partnership with Trammell Crow Residential produced an IRR of ~65% and a cash-on-cash of ~2.04x - significantly outperforming original projections,” says Jay Fuquay, Executive Vice President at Trinity Investors.
  • “We look forward to expanding our investment in Trammell Crow Residential's attainable housing strategy.”
    Allora River Ridge reaffirms one of Trinity Investors 2023 key themes, which includes focusing on new development opportunities that offer clear value creation and are less sensitive to the near-term financing environment.

Ankyra Therapeutics Presents Preliminary Phase 1 Canine Clinical Data Evaluating cANK-101 to Treat Advanced Malignant Melanoma in Dogs

Retrieved on: 
Saturday, October 14, 2023

Ankyra Therapeutics, a pre-clinical stage biotechnology company developing a new class of anchored immunotherapies to treat cancer, today presented preliminary data from an exploratory Phase 1 canine clinical study evaluating cANK-101, a canine IL-12 anchored therapeutic, to treat advanced malignant melanoma.

Key Points: 
  • Ankyra Therapeutics, a pre-clinical stage biotechnology company developing a new class of anchored immunotherapies to treat cancer, today presented preliminary data from an exploratory Phase 1 canine clinical study evaluating cANK-101, a canine IL-12 anchored therapeutic, to treat advanced malignant melanoma.
  • Fan demonstrated the safety, tolerability, and activity of cANK-101 in dogs (n=10) with advanced malignant melanoma and will inform the design of future human clinical trials.
  • “The continued collection of data on cANK-101 in dogs with advanced malignant melanoma provides us confidence in the efficacy, safety, and tolerability profile of this novel compound,” said Dr.
  • “The noticeable increase in downstream cytokines that trigger an immune response in dogs with melanoma mean that there may be new drug development opportunities to impact clinical outcomes for companion dogs.”

AutoNation Shifts Drive Pink Campaign Into High Gear to Drive Out Cancer

Retrieved on: 
Thursday, October 12, 2023

FORT LAUDERDALE, Fla., Oct. 12, 2023 /PRNewswire/ -- As part of an annual tradition, AutoNation, Inc. (NYSE: AN) gathered thousands of Associates coast to coast for Drive Pink (DRV PNK) Across America Day on October 11th.

Key Points: 
  • Associates in AutoNation stores from coast to coast joined in to delivering thousands more bags to local cancer facilities in their communities.
  • AutoNation Associates, Customers and communities have helped DRV PNK raise and donate over $35 million to cancer charities since 2013.
  • Nationally, AutoNation directs its support to BCRF, the American Cancer Society, the National Pediatric Cancer Foundation, and Zero: The End of Prostate Cancer.
  • AutoNation continues to offer its iconic DRV PNK license plate frames to drivers free of charge at all AutoNation stores, to drive awareness.

Gesund.ai Joins White House CancerX Initiative to End Cancer As We Know It

Retrieved on: 
Thursday, October 5, 2023

CAMBRIDGE, Mass., Oct. 5, 2023 /PRNewswire/ -- Gesund.ai, the company ensuring that medical artificial intelligence (AI) is safe and effective for all, today announced it has joined the White House Cancer Moonshot — CancerX — joining hundreds of public, private, and non-governmental organizations to deliver progress on the mission to end cancer as we know it. Gesund will contribute its expertise as a compliant AI Factory that allows companies to train and validate models in order to then secure FDA clearance. As the industry's leading independent third party AI validator, Gesund uses its proprietary technology and partnerships to audit and validate each model to ensure cutting-edge medical AI products can be trusted and are safe for all.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 5, 2023 /PRNewswire/ -- Gesund.ai, the company ensuring that medical artificial intelligence (AI) is safe and effective for all, today announced it has joined the White House Cancer Moonshot — CancerX — joining hundreds of public, private, and non-governmental organizations to deliver progress on the mission to end cancer as we know it.
  • CancerX is the inaugural project in The White House's national Cancer Moonshot initiative.
  • "We are honored to partner with Gesund.ai and leverage digital innovation in the fight against cancer," said Edmondo Robinson, Chief Digital Officer of Moffitt Cancer Center.
  • This partnership offers the potential to bridge the gap between the world of cancer care today and our vision for CancerX and the future."